Novo Nordisk's sales experienced impressive growth in the third quarter, with a 38% increase that brought revenue to 58.730 billion crowns, equivalent to approximately 8.3 billion dollars, excluding certain items.
This remarkable performance has been driven by growing demand for the company's flagship products designed to combat obesity and diabetes.
Novo Nordisk has achieved an impressive 47% growth in its operating profit during this period.
The company's success is largely based on products such as Wegovy and Ozempic, which have proven effective in helping people lose weight and control diabetes by reducing appetite. In fact, Wegovy sales reached almost 10 billion crowns in this period, exceeding initial expectations. However, Novo Nordisk faces challenges related to supply issues due to overwhelming demand in the United States, where the company is struggling to meet the need for these medications.
This success has led to an increase in Novo Nordisk's stock value of more than 3% in early trading, and over the past two years, the company's value has nearly doubled.
This has allowed Novo Nordisk to surpass industry giants such as Nestlé, L'Oréal, and luxury group LVMH, becoming Europe's most valuable company.
Competition in the obesity drug market has intensified, with around 40 companies, led by Eli Lilly & Co, competing for a share of this rapidly growing market.
Analysts predict that the obesity drug market could reach 100 billion dollars in 2023, and companies like Novo Nordisk and Eli Lilly could capture up to 80% of the market by 2030.
Additionally, Novo Nordisk has raised its revenue and profit forecasts for the entire year, anticipating that operating profit could increase by up to 46%. This is due to strong figures driven by the success of Wegovy and Ozempic. These medications share the same active ingredient, which works by suppressing patients' appetite and slowing the movement of food through the digestive system.
The company has also embarked on an international launch of Wegovy in countries such as Denmark, Norway, Germany, the United Kingdom, and Iceland, and has plans to expand to other markets in 2024. Additionally, the company has demonstrated in clinical trials that Wegovy not only helps with weight loss but also reduces the risk of heart disease and stroke. This could facilitate negotiations for reimbursement with insurance companies, as the cost of treatment can be considerable for patients.
Source: Bloomberg Línea
Receive all industry news in our weekly newsletter Dialéctica Científica.